Jonathan Virgo

Jonathan Virgo

Auto-generated profile, based on publicly available information

Jonathan Virgo

Medical Eye Unit, St Thomas’ Hospital, London, SE1 7EH, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

25 September 2023 in Eye
Verified
Journal Article
Open access
PDF file
EBEmilia Agata Bober
Emilia Agata Bober
KFKristina Frain
Kristina Frain
MFMajid Fotuhi
Majid Fotuhi
JVJonathan Virgo
Jonathan Virgo
EHEdward Hindle
Edward Hindle
IYIan Yeung
Ian Yeung

28 January 2019 in Eye
Verified
Journal Article
Closed access
PDF file
JVJonathan Virgo
Jonathan Virgo
GWGraeme Williams
Graeme Williams
MSMiles Stanford
Miles Stanford

18 November 2026 in Research Square
Verified
Preprint
Open access
TBTasanee Braithwaite
Tasanee Braithwaite
LLLawrence Langley
Lawrence Langley
SRShivaa Ramsewak
Shivaa Ramsewak
DJDaniel Jackson
Daniel Jackson
ASAditi Sinha
Aditi Sinha
JVJonathan Virgo
Jonathan Virgo
Background: To describe the real-world safety, steroid-sparing effect, treatment duration, infusion interval, and operational features of a medical ophthalmology-led biologic service managing non-infectious uveitis(NIU) patients with infliximab(IFX). Methods: Retrospective cohort review of patients receiving IFX for NIU at a tertiary NHS centre from March 2016 to March 2026. Primary outcomes were adverse events(AEs), serious adverse events(SAEs) and discontinuations; secondary outcomes were oral corticosteroid requirement and visual acuity. Results: 44 patients contributed 1208 months of IFX exposure (100.7 patient-years), with a median of 21.5 months(IQR 9.5–32.0). 37/44 (84%) had previously received adalimumab. AEs were reported by 20/44 (45%), including infections in 10/44 (23%) and rash in 9/44 (20%). SAEs occurred in 2/44 (5%): incident heart failure and anaphylaxis, each in 1/44 (2%). AEs led to discontinuation in 8/44 (18%). By 12 months, 10/44 (23%) had stopped IFX, most commonly due to ineffectiveness. Worse eye visual acuity changed by <15 ETDRS letters from baseline in 29/33 (88%), improved by ≥15 letters in 3/33 (9%), and worsened by ≥15 in 1/33 (3%). Among those using prednisolone at baseline, the median daily dose fell from 15 mg to 5.5 mg by month 12; at latest review (median 27 months) the median was 4.0 mg/day, with 18/21 (86%) taking ≤5 mg/day and 5/21 (24%) steroid-free. Conclusions: IFX was generally well tolerated and was associated with lower corticosteroid requirements in NIU. A medical ophthalmology-led biologic infusion service is feasible and safe but close collaboration with other medical specialties is critical for safe governance and delivery.